<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">Tumor</z:e> <z:mp ids='MP_0001651'>necrosis</z:mp> factor-like weak inducer of <z:mpath ids='MPATH_3'>apoptosis</z:mpath> (TWEAK) is a member of the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> <z:mp ids='MP_0001651'>necrosis</z:mp> factor superfamily </plain></SENT>
<SENT sid="1" pm="."><plain>TWEAK acts via binding to a cell surface receptor named Fn14 </plain></SENT>
<SENT sid="2" pm="."><plain>To study the role of this cytokine in the regulation of the permeability of the neurovascular unit (NVU) during <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo>, TWEAK activity was inhibited in <z:mp ids='MP_0002169'>wild-type</z:mp> mice with a soluble Fn14-Fc decoy receptor administered either immediately or 1 h after middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> (MCAO) </plain></SENT>
<SENT sid="3" pm="."><plain>Administration of Fn14-Fc decoy resulted in faster recovery of motor function and a 66.4%+/-10% decrease in Evans blue dye extravasation when treatment was administered immediately after MCAO and a 46.1%+/-13.1% decrease when animals were treated 1 h later (n=4, P&lt;0.05) </plain></SENT>
<SENT sid="4" pm="."><plain>Genetic deficiency of Fn14 resulted in a 60%+/-12.8% decrease in the volume of the ischemic lesion (n=6, P&lt;0.05), and a 87%+/-22% inhibition in Evans blue dye extravasation 48 h after the <z:hpo ids='HP_0003674'>onset</z:hpo> of the ischemic insult (n=6, P&lt;0.005) </plain></SENT>
<SENT sid="5" pm="."><plain>Compared with control animals, treatment with Fn14-Fc decoy or genetic deficiency of Fn14 also resulted in a significant inhibition of nuclear factor-kappaB pathway activation, matrix metalloproteinase-9 activation and basement membrane laminin degradation after MCAO </plain></SENT>
<SENT sid="6" pm="."><plain>These findings show that the cytokine TWEAK plays a role in the disruption of the structure of the NVU during <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> and that TWEAK antagonism is a potential therapeutic strategy for <z:hpo ids='HP_0011009'>acute</z:hpo> <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> </plain></SENT>
</text></document>